Try our beta test site

Investigating the Inotropic Potential of Apelin (INO-apelin)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2010 by University of Edinburgh.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
University of Edinburgh
ClinicalTrials.gov Identifier:
NCT01179061
First received: August 9, 2010
Last updated: January 13, 2011
Last verified: August 2010
  Purpose
The apelin-APJ system is a recently discover hormone system that has several important actions in the cardiovascular system. Apelin causes the heart pump with more force and also causes blood vessels to relax. Studies to date show that people with reduced pumping function of the heart have lower levels of apelin in the bloodstream compared to people with normal heart function. We have previously given apelin to healthy volunteers and people with reduced pumping function and this increases the heart's contraction. However, this has only been assessed over a short time period, around fifteen minutes, and we now want to know if this effect is seen over a longer period.

Condition Intervention
Heart Failure
Drug: Apelin
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure

Resource links provided by NLM:


Further study details as provided by University of Edinburgh:

Primary Outcome Measures:
  • cardiac output [ Time Frame: 6 hours ]
    We will assess, using thoracic bioimpedance cardiography, the change in cardiac output in response to apelin infusion


Secondary Outcome Measures:
  • Urine volume [ Time Frame: 6 hours ]
    All urine will be collected during the studya and we will assess volume and relevant biochemical/humoral factors

  • Pulmonary artery pressure [ Time Frame: 1 hour ]
    Using echocardiography we will estimate the pulmaonary artery pressure from pulmonary velocity and assess any change during the first hour of study.


Estimated Enrollment: 24
Study Start Date: August 2010
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Apelin infusion
6 hour infusion of apelin peptide into circulation
Drug: Apelin

Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.

Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.

Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine.

Placebo Comparator: Placebo
Infusion of saline into systemic circulation
Drug: Placebo
As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy volunteers:

>18yrs

Heart failure patients;

  • New York Heart Failure class II-IV
  • Ejection fractional <35% or fractional shortening <20% within previous 6months.

Exclusion Criteria:

All subjects,

  • Females of child bearing age not on adequate contraception
  • Lack of informed consent
  • Age <18yrs
  • Current involvement in any other research study
  • Systolic BP >190 or <100
  • Malignant arrhythmias
  • Renal or hepatic failure
  • Haemodynamically significant aortic stenosis
  • Severe or significant co-morbidity
  • Pacemakers

Healthy volunteers

  • Any regular medication
  • Previous history of any cardiovascular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01179061

Locations
United Kingdom
Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc
Edinburgh, United Kingdom, EH16 4SA
Gareth Barnes
Edinburgh, United Kingdom, EH16 4SA
University of Edinburgh
Edinburgh, United Kingdom, EH16 4SA
Sponsors and Collaborators
University of Edinburgh
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Gareth Barnes, University of Edinburgh
ClinicalTrials.gov Identifier: NCT01179061     History of Changes
Other Study ID Numbers: 10/S1101/18 
Study First Received: August 9, 2010
Last Updated: January 13, 2011

Keywords provided by University of Edinburgh:
Apelin
Heart failure
Pulmonary artery pressure
Inotropic
Diuretic

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on February 20, 2017